Status In progress
Process STA
ID number 915

Provisional Schedule

Final appraisal determination: 1 16 November 2017 - 30 November 2017
Expected publication 20 December 2017

Project Team

Project lead Thomas Feist

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
04 October 2017 Committee meeting: 3
26 July 2017 The company has asked to make a further submission including an improved patient access scheme. NICE has agreed that the appraisal can be referred back to the Appraisal Committee so that it can consider this new economic case. The appraisal has been temporarily suspended to allow the company to submit and the Appraisal Committee to consider new evidence on the cost effectiveness of palbociclib with the updated patient access scheme in place. We will provide an update on timelines for this appraisal as soon as they are available.
08 June 2017 Committee meeting: 2
31 March 2017 The second committee discussion of palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915] will be held on 8 June 2017 at NICE London Offices, Prince of Wales Suite 10 Spring Gardens SW1A 2BU.
29 March 2017 Following communication with the company, we have decided to postpone the second committee meeting to discuss palbociclib in combination with an aromatase inhibitor for previously untreated metastatic, hormone receptor-positive, HER2-negative breast cancer [ID915]. This is to allow the company to submit an updated evidence package including more data from the PALOMA-1 study. The discussion of this topic on 06 April is therefore cancelled. We will update you when we have a new date for the committee discussion.
03 February 2017 - 24 February 2017 Appraisal consultation
11 January 2017 Committee meeting: 1
01 August 2016 Invitation to participate
21 June 2016 Draft scope documents
13 May 2016 Referral

For further information on how we develop guidance, please see our page about NICE technology appraisal guidance